Aligos Therapeutics Inc (ALGS)

$0.52

+0.01

(+1.66%)

Market is closed - opens 7 PM, 15 Jul 2024

Insights on Aligos Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 6.88M → 986.0K (in $), with an average decrease of 44.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -18.04M → -34.86M (in $), with an average decrease of 39.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 81.1% return, outperforming this stock by 126.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 227.9% return, outperforming this stock by 324.5%

Performance

  • $0.51
    $0.54
    $0.52
    downward going graph

    2.19%

    Downside

    Day's Volatility :5.41%

    Upside

    3.29%

    downward going graph
  • $0.35
    $1.20
    $0.52
    downward going graph

    33.04%

    Downside

    52 Weeks Volatility :70.98%

    Upside

    56.67%

    downward going graph

Returns

PeriodAligos Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-41.89%
6.7%
0.0%
6 Months
-26.77%
5.5%
0.0%
1 Year
-45.85%
14.3%
0.0%
3 Years
-96.56%
15.1%
-21.0%

Highlights

Market Capitalization
39.9M
Book Value
$0.79
Earnings Per Share (EPS)
-1.05
Wall Street Target Price
7.0
Profit Margin
0.0%
Operating Margin TTM
-2235.9%
Return On Assets TTM
-42.83%
Return On Equity TTM
-137.79%
Revenue TTM
13.8M
Revenue Per Share TTM
0.15
Quarterly Revenue Growth YOY
-63.800000000000004%
Gross Profit TTM
-71.2M
EBITDA
-84.1M
Diluted Eps TTM
-1.05
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.73
EPS Estimate Next Year
-0.71
EPS Estimate Current Quarter
-0.19
EPS Estimate Next Quarter
-0.18

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Aligos Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1246.15%

Current $0.52
Target $7.00

Technicals Summary

Sell

Neutral

Buy

Aligos Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aligos Therapeutics Inc
Aligos Therapeutics Inc
2.32%
-26.77%
-45.85%
-96.56%
-96.5%
Moderna, Inc.
Moderna, Inc.
-16.37%
18.89%
-4.07%
-48.35%
748.18%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.16%
17.36%
52.58%
90.65%
268.9%
Novo Nordisk A/s
Novo Nordisk A/s
-0.29%
33.6%
81.13%
227.9%
496.35%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.03%
11.71%
40.03%
146.43%
177.11%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aligos Therapeutics Inc
Aligos Therapeutics Inc
NA
NA
NA
-0.73
-1.38
-0.43
NA
0.79
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aligos Therapeutics Inc
Aligos Therapeutics Inc
Buy
$39.9M
-96.5%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
748.18%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
268.9%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
496.35%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
177.11%
31.94
39.46%

Institutional Holdings

  • Armistice Capital, LLC

    8.83%
  • EcoR1 Capital, LLC

    8.18%
  • Deep Track Capital, LP

    7.81%
  • Vivo Capital, LLC

    4.54%
  • Altitude Crest Partners Inc

    3.64%
  • Adage Capital Partners Gp LLC

    3.16%

Company Information

aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-㟠agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california.

Organization
Aligos Therapeutics Inc
Employees
67
CEO
Dr. Lawrence M. Blatt MBA, Ph.D.
Industry
Health Technology

FAQs